Stockreport

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals [Yahoo! Finance]

Quoin Pharmaceuticals, Ltd. - American Depositary Shares  (QNRX) 
PDF Quoin Pharmaceuticals (NASDAQ:QNRX) has two active Netherton Syndrome (NS) studies that are being conducted concurrently to evaluate lead asset QRX003 for the treatment [Read more]